Learn about ZULRESSO®, an FDA-approved treatment for PPD in adults. See full Prescribing Information, Boxed Warning, and Important Safety Info.

2025年1月1日 · ZULRESSO ® (brexanolone) is administered continuously by intravenous infusion (into the vein) over 2.5 days (60 hours). You are treated with Zulresso in a healthcare setting, a Treating Center, where you can be monitored by a healthcare provider throughout your treatment because of the risk of excessive sedation or sudden loss of consciousness.

2025年1月1日 · Learn how ZULRESSO® is used to help treat postpartum depression (PPD) in adults. See full Prescribing Info, Boxed Warning, and Important Safety Info.

ZULRESSO® (brexanolone) may provide rapid improvement of depressive symptoms in 2.5 days (60 hours). *Individual results may vary. ZULRESSO is administered as a continuous intravenous infusion into the vein over 2.5 days (60 hours). ZULRESSO may cause you to feel very sleepy (excessive sedation) or pass out (loss of consciousness).

ZULRESSO ® (brexanolone) is a prescription medicine used to treat Postpartum Depression in individuals 15 years and older. IMPORTANT SAFETY INFORMATION ZULRESSO can cause serious side effects, including: Excessive sedation and sudden loss of consciousness.

Eligible commercially insured patients may pay as little as $0. Download the ZULRESSO ® (brexanolone) Financial Assistance Brochure to review financial support options.

As of January 1, 2025, ZULRESSO ® (brexanolone) is no longer commercially available in the U.S. Please contact us at Sage Central ® Patient Support at 1-844-472-4379 if you have any questions or need more information

For all your questions regarding your treatment with ZULRESSO ® (brexanolone), including selecting a Treating Center, your healthcare provider should be your primary resource. ZULRESSO may cause you to feel very sleepy (excessive sedation) or pass out (loss of consciousness).

Concerns about the cost of ZULRESSO ® (brexanolone) should not prevent you from seeking the treatment your healthcare provider has prescribed. Sage Central offers several financial assistance programs that can help reduce out-of-pocket costs related to your treatment.

2025年1月1日 · ZULRESSO ® (brexanolone) is the first FDA-approved treatment for postpartum depression in individuals 15 and older. Fast results: In clinical studies, moms treated with ZULRESSO experienced a greater reduction of depressive symptoms vs placebo in …